Hangzhou Eli Radiopharma Co., Ltd.
PrivateLast Round
Series A
Nov 12, 2026
Total Funding Raised
$87.76M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Hangzhou Eli Radiopharma Co., Ltd. operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Series A round in November 2026.
Hangzhou Eli Radiopharma Co., Ltd. is a pharmaceutical company that develops targeted radiopharmaceuticals for the diagnosis and treatment of oncology and neurological diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical Imaging, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hangzhou Eli Radiopharma Co., Ltd. Comparables
Compare Hangzhou Eli Radiopharma Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AlphaGen Therapeutics | 87% | |
| Bivision Biomedical Technology (Nanjing) Co., Ltd. | 85% | |
| Boomray Pharmaceuticals Co., Ltd. | 85% |
For institutional investors. Book with your work email.
Hangzhou Eli Radiopharma Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 12, 2026 | ||||
| VC Round | Mar 12, 2026 | ||||
| Angel | Sep 25, 2025 | ||||
| Angel | Dec 24, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Hangzhou Eli Radiopharma Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KHK & Partners | Series A, Angel |
| InnoPinnacle Fund Management | Series A |
| BioClub | Series A, VC Round |
| YuanBio Venture Capital | Angel |
| Bayland Capital | Series A |
| Skyfield Capital | Series A |
| Delian Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 12, 2026
$60M round led by Bayland Capital and Huagai Capital.
- Mar 12, 2026
$15M round led by BioClub.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 12, 2026
On Nov 11th '26, Eli Radiopharma receives $60M in Series A financing led by Huagai Capital, with Bayland Capital as co-lead, to advance its radiopharmaceutical pipeline toward clinical development in China.
For institutional investors. Book with your work email.
Hangzhou Eli Radiopharma Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Hangzhou Eli Radiopharma Co., Ltd.'s valuation, stock price, and market status.
Is Hangzhou Eli Radiopharma Co., Ltd. a public or private company?
Hangzhou Eli Radiopharma Co., Ltd. is a private company.
What is the current stock price of Hangzhou Eli Radiopharma Co., Ltd.?
Hangzhou Eli Radiopharma Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Hangzhou Eli Radiopharma Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hangzhou Eli Radiopharma Co., Ltd. worth (valuation)?
Valuation information for Hangzhou Eli Radiopharma Co., Ltd. is not publicly available.
Can I buy Hangzhou Eli Radiopharma Co., Ltd. stock?
Hangzhou Eli Radiopharma Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hangzhou Eli Radiopharma Co., Ltd.'s last funding round?
Hangzhou Eli Radiopharma Co., Ltd.'s most recent funding round was Series A on November 12, 2026.
Who are the main investors in Hangzhou Eli Radiopharma Co., Ltd.?
Key investors in Hangzhou Eli Radiopharma Co., Ltd. include Bayland Capital, Huagai Capital.
Will Hangzhou Eli Radiopharma Co., Ltd. IPO soon?
No public IPO plans have been announced for Hangzhou Eli Radiopharma Co., Ltd..
How can I track Hangzhou Eli Radiopharma Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Hangzhou Eli Radiopharma Co., Ltd.'s shares on secondary markets.